Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Nonradiographic Axial Spondyloarthritis (Phase 3)
2015-000289-67Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Ustekinumab with Placebo (2 arms). Primary endpoint: ASAS20 response at Week 24. Started May 2015; status: completed.
02
Drugs
ustekinumab
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2015-000289-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000289-67.